Concepedia

Margaret McAlary

MM

Statistics

Publications

5

Citations

2.2K

H-Index

5

Active since

2001

Affiliations

Novartis (United States)(Current)

Peoria campus of the University of Illinois System

Margaret McAlary is an author at Novartis (United States) specializing in allergy, life sciences, and ige-mediated allergy.

Publications per year

2001–2004

5

Publications

5

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

William W. Busse, Jonathan Corren, Bobby Q. Lanier et al. · Journal of Allergy and Clinical Immunology · 2001 · 1.3K citations · Full text

, , +16

Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)

Henry Milgrom, William Berger, Anjuli Nayak et al. · PEDIATRICS · 2001 · 519 citations

, , +17

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

William E. Berger, Niroo Gupta, Margaret McAlary et al. · Annals of Allergy Asthma & Immunology · 2003 · 183 citations

, , +16

Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma

Robert F. Lemanske, Anjuli Nayak, Margaret McAlary et al. · PEDIATRICS · 2002 · 148 citations

, , +16

Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.

Anjuli Nayak, Thomas B. Casale, S. David Miller et al. · PubMed · 2004 · 45 citations

, , +17

1–5 of 5